Camptothecin ADC Linker-Payload Design for Solid Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing camptothecin derivatives and antibody-drug conjugates (ADCs) face challenges with tumor cell resistance and limited efficacy against solid tumors, necessitating the development of novel camptothecin derivatives with potent cytotoxic activity and improved tumor targeting.
Innovation Solution
Development of antibody-drug conjugates comprising specific camptothecin derivatives linked via various linker units to antibodies, forming pharmaceutical compositions with enhanced cytotoxic activity and reduced toxicity, targeting a wide range of cancers including solid tumors and hematological malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If camptothecin derivatives are used as payloads in ADCs, then potent cytotoxic effects are achieved, but tumor cell resistance develops through reduced intracellular drug accumulation
Solution Approach 1:
The patent modifies the chemical structure of camptothecin derivatives by introducing specific substituents at positions 9, 10, and 20 of the camptothecin core structure. These structural parameter changes create novel derivatives (e.g., with R1-H or C1-6 alkyl, R2-H or C1-6 alkyl, R3-H or C1-6 alkyl) that alter drug properties to overcome resistance mechanisms while maintaining cytotoxic potency
Solution Approach 2:
The patent creates composite antibody-drug conjugates by linking modified camptothecin derivatives to antibodies through various linker units. This composite structure combines the tumor-targeting capability of antibodies with the enhanced cytotoxic activity of modified camptothecin derivatives, achieving both potent efficacy and reduced resistance
2Strength
If traditional small-molecule cytotoxic drugs are used, then potent cytotoxic effects are achieved, but toxicity and side effects increase
Solution Approach 1:
The patent uses antibodies as intermediary carriers to deliver modified camptothecin derivatives specifically to tumor cells. The antibody component enables selective binding to tumor cell surface antigens, ensuring that the cytotoxic payload is delivered only to target cells rather than systemically, thereby reducing off-target toxicity and side effects
Solution Approach 2:
The patent achieves localized cytotoxic action by conjugating camptothecin derivatives to antibodies that specifically recognize tumor cell markers. This ensures that the potent cytotoxic effect is concentrated at the tumor site (local quality) rather than distributed throughout the body, maximizing therapeutic efficacy while minimizing systemic toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel camptothecin derivatives and ADCs exhibit superior tumor-killing activity, favorable tolerability, and strong bystander effects, effectively treating a variety of cancers with reduced side effects and improved therapeutic window.
Implementation Method 1
an antibody (Ab) responsible for selectively recognizing a tumor cell surface antigen
Implementation Method 2
ADC drugs are internalized into the cells via endocytosis
Implementation Method 3
Camptothecin (CPT) is a small-molecule, plant-derived anticancer agent that functions as a DNA topoisomerase I inhibitor
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 2a~2b
AI summary
The present invention relates to camptothecin derivatives, their linker-payload conjugates, and antibody-drug conjugates, as well as pharmaceutically acceptable salts or esters, solvates, tautomers, stereoisomers, prodrugs, or isotopically labeled forms thereof, for use in the treatment or prevention of cancer. The invention further relates to a pharmaceutical composition comprising the camptothecin derivatives, their linker-payload conjugates, or antibody-drug conjugates; methods for the preparation of the same; and the use thereof.